A5093851708- Hematopoietic Stem Cell Transplantation
- T-cell and B-cell Immunology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cystic Fibrosis Research Advances
- Renal Transplantation Outcomes and Treatments
Hospital Clínic de Barcelona
2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2024
Universitat de Barcelona
2024
PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac complications. This pilot study evaluates the efficacy toxicity a reduced dose (40 mg/kg/day) combined tacrolimus in 22 peripheral blood HLA-matched alloHSCT patients. At day +100, cumulative incidences grade II–IV III–IV acute GVHD were 18.2% 4.5%, respectively. No IV or steroid-refractory disease...
Abstract Background Most patients with haematological malignancies who undergo allogeneic haematopoietic stem cell transplant (HSCT) receive chemotherapy before the to control disease. Certain drugs can cause lung toxicity. Conversely, in chronic respiratory conditions, 6‐min walking test (6MWT) and desaturation–distance ratio (DDR) have demonstrated prognostic significance. Our objective was determine whether 6MWD DDR, assessed prior HSCT, a impact on survival at 24 months post‐HSCT....